260 related articles for article (PubMed ID: 15282359)
1. Beyond fast track for drug approvals.
Roberts TG; Chabner BA
N Engl J Med; 2004 Jul; 351(5):501-5. PubMed ID: 15282359
[No Abstract] [Full Text] [Related]
2. Assessing supplement safety--the FDA's controversial proposal.
Cohen PA
N Engl J Med; 2012 Feb; 366(5):389-91. PubMed ID: 22276780
[No Abstract] [Full Text] [Related]
3. Good drug, bad luck: business, regulatory issues can create obstacles for drug development.
Goldman B
J Natl Cancer Inst; 2004 Nov; 96(21):1573-4. PubMed ID: 15523084
[No Abstract] [Full Text] [Related]
4. The drug that could have been.
Schultz S
US News World Rep; 2002 Aug; 133(7):18, 20-3. PubMed ID: 12195678
[No Abstract] [Full Text] [Related]
5. Bolstering the FDA's drug-safety authority.
Schultz WB
N Engl J Med; 2007 Nov; 357(22):2217-9. PubMed ID: 18046024
[No Abstract] [Full Text] [Related]
6. The Food and Drug Administration's early access and fast-track approval initiatives: how have they worked?
Shulman SR; Brown JS
Food Drug Law J; 1995; 50(4):503-31. PubMed ID: 10343017
[No Abstract] [Full Text] [Related]
7. Experience With the Priority Review Voucher Program for Drug Development.
Kesselheim AS; Maggs LR; Sarpatwari A
JAMA; 2015 Oct; 314(16):1687-8. PubMed ID: 26414802
[No Abstract] [Full Text] [Related]
8. Expensive cancer therapies: unintended effects.
Delude CM
J Natl Cancer Inst; 2015 Jan; 107(1):497. PubMed ID: 25564602
[No Abstract] [Full Text] [Related]
9. Prescription drugs marketed in the United States should be approved by the FDA.
Shepherd MD; Curtiss FR
J Manag Care Pharm; 2003; 9(4):366-7. PubMed ID: 14613456
[TBL] [Abstract][Full Text] [Related]
10. New fee structure proposed by FDA might lead to more talk.
Waters H
Nat Med; 2011 Oct; 17(10):1159. PubMed ID: 21988966
[No Abstract] [Full Text] [Related]
11. Doctor explains why he blew the whistle.
Petersen M
N Y Times Web; 2003 Mar; ():C1, C2. PubMed ID: 12812161
[No Abstract] [Full Text] [Related]
12. TransMolecular receives FDA approval for 131-I-TM-601 IND application.
Expert Rev Anticancer Ther; 2002 Apr; 2(2):139. PubMed ID: 12113233
[No Abstract] [Full Text] [Related]
13. Pros and cons of off-label promotion investigations and prosecutions.
Loucks MK
Food Drug Law J; 2006; 61(3):577-83. PubMed ID: 16989041
[No Abstract] [Full Text] [Related]
14. Accelerated approval of oncology drugs: can we do better?
Ellenberg SS
J Natl Cancer Inst; 2011 Apr; 103(8):616-7. PubMed ID: 21422401
[No Abstract] [Full Text] [Related]
15. 'Fast-track' drug approvals hit speed bumps in Japan.
Sipp D
Nat Med; 2004 Sep; 10(9):883. PubMed ID: 15340398
[No Abstract] [Full Text] [Related]
16. Paying for drug approvals--who's using whom?
Avorn J
N Engl J Med; 2007 Apr; 356(17):1697-700. PubMed ID: 17435083
[No Abstract] [Full Text] [Related]
17. Drug safety special: the safety catch.
Wadman M
Nature; 2005 Mar; 434(7033):554-6. PubMed ID: 15800591
[No Abstract] [Full Text] [Related]
18. Drug safety on trial.
Nature; 2005 Mar; 434(7033):545. PubMed ID: 15800579
[No Abstract] [Full Text] [Related]
19. Pharmaceutical promotion and First Amendment rights.
Troy DE; Gottlieb S
N Engl J Med; 2008 Jul; 359(5):536; author reply 536-7. PubMed ID: 18669437
[No Abstract] [Full Text] [Related]
20. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
Roman A
Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
[No Abstract] [Full Text] [Related]
[Next] [New Search]
